---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069021"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:22:31.655733+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Movano Health Q2 2024 operating loss narrows to $6.4M; Evie Ring back in stock Sept 17

## Summary
- Operating loss of $6.4M improved from $7.4M in Q2 2023; no revenue reported as refunds offset deferred revenue.
- Shipped 1,837 Evie Rings in Q2; cash and equivalents $16.9M at June 30, 2024.
- Evie Ring expected back in stock September 17, 2024; brand partnership with Heidi D'Amelio announced.
- FDA live meeting scheduled mid-August for EvieMED 510(k) clearance; B2B opportunities with pharma and payor advancing.
- April 2024 $24.1M private placement closed with tier-1 medical device company investment.

## SEC filing metadata
- accession: 0001213900-24-069021
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390024069021/0001213900-24-069021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390024069021/ea0211408-8k_movano.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069021
- JSON: https://secwatch.observer/filing/0001213900-24-069021.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.